DR4, referred to as TRAIL Receptor-1, is a novel death domain containing receptor whose ligand has been identified as TRAIL or apoptosis-inducing ligand 2 (Apo2L). It is a member of the TNF superfamily of receptors that induce apoptosis. It is expressed in most human tissues including spleen, peripheral blood leukocytes, small intestine, and thymus.
Immunogeno
synthetic peptide corresponding to amino acids 1-20 of the N-terminal of the mature human DR4.
Applicazioni
Anti-DR4 antibody produced in rabbit is suitable for microarray and immunoblotting at a working dilution of 1:500-1:1000 using total HeLa, K562, and Jurkat whole cell lysates. It was used as a primary antibody in the immunodetection of DR4 in cell lysate of human small cell lung carcinoma cells. It was used as a primary antibody in the immunoblot analysis of fetal and adenocarcinoma epithelial colon cells in a study.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below. Western Blotting (1 paper)
Azioni biochim/fisiol
DR4 induces apoptosis in a variety of human tumor cell lines, but not in normal cells and activates NF-κB.
Stato fisico
Solution in phosphate buffered saline containing 0.02% sodium azide
Esclusione di responsabilità
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
The resistance of transformed epithelial cells to a detachment-induced apoptosis (anoikis) can significantly affect their susceptibility to anticancer therapy. We showed that detachment of both fetal (FHC) and adenocarcinoma (HT-29) human colon epithelial cells resulted in the activation of the
TRAIL is considered as a promising anti-cancer agent, because of its ability to induce apoptosis in cancer but not in most normal cells. However, growing evidence exist that many cancer cells are resistant to its apoptotic effects. SCLC is a
A novel tumor necrosis factor (TNF) family member has been cloned and characterized. This protein, designated TNF-related apoptosis-inducing ligand (TRAIL), consists of 281 and 291 aa in the human and murine forms, respectively, which share 65% aa identity. TRAIL is
TRAIL induces apoptosis through two closely related receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Here we show that TRAIL-R1 can associate with TRAIL-R2, suggesting that TRAIL may signal through heteroreceptor signaling complexes. Both TRAIL receptors bind the adaptor molecules FADD and
Science (New York, N.Y.), 276(5309), 111-113 (1997-04-04)
TRAIL (also known as Apo-2L) is a member of the tumor necrosis factor (TNF) ligand family that rapidly induces apoptosis in a variety of transformed cell lines. The human receptor for TRAIL was found to be an undescribed member of
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..